Innovation1 Biotech Inc.

$ Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000147793224000223 Filed on January 17, 2024

Income Statement

Concept	2024 Q1	2023 Q3	2023

Balance Sheet

Concept	2024 Q1	2023 Q3	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents		$49.85K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses		$15.00K
Receivables
Other Receivables
Total Short-Term Assets		$72.74K
YoY Change		-74.65%
LONG-TERM ASSETS
Property, Plant & Equipment		$1.569K
YoY Change		-40.0%
Goodwill
YoY Change
Intangibles		$1.680K
YoY Change		0.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$3.249K
YoY Change		-99.99%
TOTAL ASSETS
Total Short-Term Assets		$72.74K
Total Long-Term Assets		$3.249K
Total Assets		$75.99K
YoY Change		-99.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$349.3K
YoY Change		220.81%
Accrued Expenses		$1.072M
YoY Change		584.9%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$3.287M
YoY Change		-88.97%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$219.0K
YoY Change		-98.06%
TOTAL LIABILITIES
Total Short-Term Liabilities		$3.287M
Total Long-Term Liabilities		$219.0K
Total Liabilities		$3.506M
YoY Change		-91.47%
SHAREHOLDERS EQUITY
Retained Earnings		-$58.63M
YoY Change		31.6%
Common Stock		$20.47K
YoY Change		2.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$3.430M
YoY Change
Total Liabilities & Shareholders Equity		$75.99K
YoY Change		-99.83%

Cashflow Statement

Concept	2024 Q1	2023 Q3	2023

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001629205
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--08-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20020239	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20470239	shares
CY2023	ivbt	Fv Of350000 Shares Transferred To Buyer013 Per Share FvOf350000SharesTransferredToBuyer013PerShare	-45500	usd
CY2023Q3	us-gaap	Other Liabilities OtherLiabilities	110818	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-143956	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-08-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-55852
CY2023	dei	Entity Registrant Name EntityRegistrantName	INNOVATION1 BIOTECH INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2275255
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	7 Grand View Avenue
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Somerville
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02143
CY2023	dei	City Area Code CityAreaCode	617
CY2023	dei	Local Phone Number LocalPhoneNumber	447-8299
CY2023	dei	Security12g Title Security12gTitle	Common stock, $.001 par value
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Entity Shell Company EntityShellCompany	true
CY2023Q1	dei	Entity Public Float EntityPublicFloat	6243650	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22470239	shares
CY2023	dei	Auditor Name AuditorName	Fruci & Associates II, PLLC
CY2023	dei	Auditor Firm AuditorFirmId	5525
CY2023	dei	Auditor Location AuditorLocation	Spokane, Washington
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49849	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	156486	usd
CY2023Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	7895	usd
CY2022Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	56421	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	15000	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	74049	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	72744	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	286956	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1569	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2615	usd
CY2023Q3	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	1680	usd
CY2022Q3	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	1680	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	0	usd
CY2022Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	42980076	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	0	usd
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	482086	usd
CY2023Q3	us-gaap	Security Deposit SecurityDeposit	0	usd
CY2022Q3	us-gaap	Security Deposit SecurityDeposit	210000	usd
CY2023Q3	us-gaap	Other Assets OtherAssets	3248	usd
CY2022Q3	us-gaap	Other Assets OtherAssets	43676457	usd
CY2023Q3	us-gaap	Assets Assets	75993	usd
CY2022Q3	us-gaap	Assets Assets	43963413	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	349301	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	106215	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1072108	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39558	usd
CY2023Q3	ivbt	Accrued Expenses Related Parties AccruedExpensesRelatedParties	106923	usd
CY2022Q3	ivbt	Accrued Expenses Related Parties AccruedExpensesRelatedParties	116977	usd
CY2023Q3	ivbt	Mioxal Liability Current Portion MioxalLiabilityCurrentPortion	0	usd
CY2022Q3	ivbt	Mioxal Liability Current Portion MioxalLiabilityCurrentPortion	28500000	usd
CY2023Q3	ivbt	Related Party Payable RelatedPartyPayable	0	usd
CY2022Q3	ivbt	Related Party Payable RelatedPartyPayable	2665	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	199203	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	10000	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	10000	usd
CY2023Q3	us-gaap	Dividends Payable Current DividendsPayableCurrent	1748625	usd
CY2022Q3	us-gaap	Dividends Payable Current DividendsPayableCurrent	837798	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3286957	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	29812416	usd
CY2023Q3	ivbt	Operating Lease Liability Non Current OperatingLeaseLiabilityNonCurrent	0	usd
CY2022Q3	ivbt	Operating Lease Liability Non Current OperatingLeaseLiabilityNonCurrent	298423	usd
CY2023Q3	ivbt	Mioxal Liability Non Current Portion MioxalLiabilityNonCurrentPortion	0	usd
CY2022Q3	ivbt	Mioxal Liability Non Current Portion MioxalLiabilityNonCurrentPortion	11000000	usd
CY2023Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	218999	usd
CY2022Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	0	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	218999	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11298423	usd
CY2023Q3	us-gaap	Liabilities Liabilities	3505956	usd
CY2022Q3	us-gaap	Liabilities Liabilities	41110839	usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20470239	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20020239	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	20470	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	20020	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	55171921	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47375513	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58630438	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-44551043	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-3429963	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	2852574	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	75993	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43963413	usd
CY2023	us-gaap	Revenues Revenues	0	usd
CY2022	us-gaap	Revenues Revenues	0	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2023	us-gaap	Gross Profit GrossProfit	0	usd
CY2022	us-gaap	Gross Profit GrossProfit	0	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	10267	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	4914	usd
CY2023	us-gaap	Legal Fees LegalFees	35500	usd
CY2022	us-gaap	Legal Fees LegalFees	398033	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	341927	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	362359	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	80500	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2023	ivbt	Lease Termination Claim LeaseTerminationClaim	100000	usd
CY2022	ivbt	Lease Termination Claim LeaseTerminationClaim	0	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	308023	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	477392	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	201166	usd
CY2023	us-gaap	Salaries And Wages SalariesAndWages	475123	usd
CY2022	us-gaap	Salaries And Wages SalariesAndWages	1259519	usd
CY2023	us-gaap	Depreciation Depreciation	1046	usd
CY2022	us-gaap	Depreciation Depreciation	523	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2545839	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	1367386	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	5249745	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-1367386	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-5249745	usd
CY2023	us-gaap	Interest Expense InterestExpense	251826	usd
CY2022	us-gaap	Interest Expense InterestExpense	5514	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	0	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	13638	usd
CY2023	ivbt	Impairment Expense ImpairmentExpense	3480076	usd
CY2022	ivbt	Impairment Expense ImpairmentExpense	35780148	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-170857	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-143956	usd
CY2023	us-gaap	Other Nonrecurring Income Expense OtherNonrecurringIncomeExpense	1059835	usd
CY2022	us-gaap	Other Nonrecurring Income Expense OtherNonrecurringIncomeExpense	0	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4620880	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	35628068	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5988266	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-40877813	usd
CY2023	ivbt	Deemed Dividend Related To Series B And B1 Convertible Preferred Stock Down Round Provision DeemedDividendRelatedToSeriesBAndB1ConvertiblePreferredStockDownRoundProvision	-7180301	usd
CY2022	ivbt	Deemed Dividend Related To Series B And B1 Convertible Preferred Stock Down Round Provision DeemedDividendRelatedToSeriesBAndB1ConvertiblePreferredStockDownRoundProvision	0	usd
CY2023	us-gaap	Dividends Preferred Stock DividendsPreferredStock	910829	usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	699602	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14079396	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-41577415	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.70
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.73
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20184212	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15225781	shares
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	2852574	usd
CY2022Q4	ivbt	Convertible Notes Payable Bcf And Warrant ConvertibleNotesPayableBcfAndWarrant	50000	usd
CY2022Q4	ivbt	Dividends On Preferred Stock Accrued DividendsOnPreferredStockAccrued	-187572	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-631666	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2083336	usd
CY2023Q1	ivbt	Dividends On Preferred Stock Accrued DividendsOnPreferredStockAccrued	-273939	usd
CY2023Q1	ivbt	Convertible Notes Payable Bcf And Warrant ConvertibleNotesPayableBcfAndWarrant	250000	usd
CY2023Q1	ivbt	Common Shares To Be Issued CommonSharesToBeIssued	22500	usd
CY2023Q1	ivbt	Adjustment Of Additional Paid In Capitaldeemed Dividends AdjustmentOfAdditionalPaidInCapitaldeemedDividends	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-603390	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1478507	usd
CY2023Q2	ivbt	Dividends On Preferred Stock Accrued DividendsOnPreferredStockAccrued	-221863	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	102900	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-22400	usd
CY2023Q2	ivbt	Convertible Notes Payable Bcf And Warrant ConvertibleNotesPayableBcfAndWarrant	213557	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-298857	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1251844	usd
CY2023Q3	ivbt	Dividends On Preferred Stock Accrued DividendsOnPreferredStockAccrued	-227455	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	usd
CY2023Q3	ivbt	Adjustment Of Additional Paid In Capitaldeemed Dividends AdjustmentOfAdditionalPaidInCapitaldeemedDividends	0	usd
CY2023Q3	ivbt	Convertible Notes Payable Bcf And Warrant ConvertibleNotesPayableBcfAndWarrant	0	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-4454352	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-3429963	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-224839	usd
CY2021Q4	ivbt	Series B1 Preferred Stock Purchase Agreements Amount SeriesB1PreferredStockPurchaseAgreementsAmount	4000000	usd
CY2021Q4	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	40654827	usd
CY2021Q4	ivbt	Dividends On Preferred Stock Accrued DividendsOnPreferredStockAccrued	-136887	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-239853	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	44053248	usd
CY2022Q1	ivbt	Dividends On Preferred Stock Accrued DividendsOnPreferredStockAccrued	-187571	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1779054	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	42086623	usd
CY2022Q2	ivbt	Dividends On Preferred Stock Accrued DividendsOnPreferredStockAccrued	-187571	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1609876	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	40289176	usd
CY2022Q3	ivbt	Dividends On Preferred Stock Accrued DividendsOnPreferredStockAccrued	-187572	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-37249031	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5988266	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-40877813	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1047	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	523	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	51652	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	137739	usd
CY2023	ivbt	Amortization Of Mioxal Asset AmortizationOfMioxalAsset	0	usd
CY2022	ivbt	Amortization Of Mioxal Asset AmortizationOfMioxalAsset	2408100	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	218998	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
CY2023	ivbt	Termination Of Right Of Use Asset Lease TerminationOfRightOfUseAssetLease	430434	usd
CY2022	ivbt	Termination Of Right Of Use Asset Lease TerminationOfRightOfUseAssetLease	0	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	103000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
CY2023	ivbt	Impairment Expenses ImpairmentExpenses	3480076	usd
CY2022	ivbt	Impairment Expenses ImpairmentExpenses	35780148	usd
CY2023	ivbt	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	-170857	usd
CY2022	ivbt	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	-143956	usd
CY2023	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-19236	usd
CY2022	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-56421	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	269049	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-270049	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	48526	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-248569	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-41523	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-2665	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-64600	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1032550	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0	usd
CY2023	ivbt	Increase Decrease In Accrued Liabilities Related Parties IncreaseDecreaseInAccruedLiabilitiesRelatedParties	174067	usd
CY2022	ivbt	Increase Decrease In Accrued Liabilities Related Parties IncreaseDecreaseInAccruedLiabilitiesRelatedParties	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-620195	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3127852	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3138	usd
CY2023	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	0	usd
CY2022	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	850000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-853138	usd
CY2023	ivbt	Proceeds Form Series B1 Preferred Stock Purchase Agreements ProceedsFormSeriesB1PreferredStockPurchaseAgreements	0	usd
CY2022	ivbt	Proceeds Form Series B1 Preferred Stock Purchase Agreements ProceedsFormSeriesB1PreferredStockPurchaseAgreements	4000000	usd
CY2023	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	26891	usd
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	0	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	486667	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	513558	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4000000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-106637	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	19010	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	156486	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	137476	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49849	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	156486	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	37802	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	ivbt	Right Of Use Asset And Lease Liability Recognition At Inception RightOfUseAssetAndLeaseLiabilityRecognitionAtInception	0	usd
CY2022	ivbt	Right Of Use Asset And Lease Liability Recognition At Inception RightOfUseAssetAndLeaseLiabilityRecognitionAtInception	619825	usd
CY2023	ivbt	Preferred Stock Dividends Accrued PreferredStockDividendsAccrued	461511	usd
CY2022	ivbt	Preferred Stock Dividends Accrued PreferredStockDividendsAccrued	699601	usd
CY2023	ivbt	Payables Settled With Intangible Assets PayablesSettledWithIntangibleAssets	0	usd
CY2022	ivbt	Payables Settled With Intangible Assets PayablesSettledWithIntangibleAssets	117000	usd
CY2023	ivbt	Non Cash Deemed Dividends Preferred Stock NonCashDeemedDividendsPreferredStock	7180301	usd
CY2022	ivbt	Non Cash Deemed Dividends Preferred Stock NonCashDeemedDividendsPreferredStock	0	usd
CY2023	ivbt	Transfer Of Mioxal Asset TransferOfMioxalAsset	39600000	usd
CY2022	ivbt	Transfer Of Mioxal Asset TransferOfMioxalAsset	0	usd
CY2023	ivbt	Transfer Of Mioxal Liabilities TransferOfMioxalLiabilities	-39500000	usd
CY2022	ivbt	Transfer Of Mioxal Liabilities TransferOfMioxalLiabilities	0	usd
CY2023	ivbt	Receivable Created With Mioxal Asset Sale ReceivableCreatedWithMioxalAssetSale	-100000	usd
CY2022	ivbt	Receivable Created With Mioxal Asset Sale ReceivableCreatedWithMioxalAssetSale	0	usd
CY2023	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	0	usd
CY2022	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	40654827	usd
CY2023	us-gaap	Nonoperating Gains Losses NonoperatingGainsLosses	-5988266	usd
CY2023Q3	ivbt	Working Capital Deficit WorkingCapitalDeficit	-3214213	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58630438	usd
CY2023	us-gaap	Reclassifications Reclassifications	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Certain prior year amounts may have been reclassified for comparative purposes to conform to the current-year financial statement presentation. These reclassifications had no effect on previously reported results.</p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results could differ from those estimates. Estimates are used when accounting for fair value calculations, including those related to embedded conversion features of outstanding convertible notes payable. </p>
CY2023	ivbt	Obsolete Inventory Written Off ObsoleteInventoryWrittenOff	0	usd
CY2022	ivbt	Obsolete Inventory Written Off ObsoleteInventoryWrittenOff	17000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2023	ivbt	Total Estimated Value Of Intangible Assets TotalEstimatedValueOfIntangibleAssets	0	usd
CY2023	ivbt	Carrying Value Of Intangible Assets CarryingValueOfIntangibleAssets	3380076	usd
CY2023	ivbt	Impairment Expense On Intangible Assets ImpairmentExpenseOnIntangibleAssets	3380076	usd
CY2023	ivbt	Interest Rate InterestRate	0.0008	pure
CY2023Q1	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	484668	usd
CY2023Q1	us-gaap	Inventory Real Estate Other InventoryRealEstateOther	4668	usd
CY2023	us-gaap	Depreciation Depreciation	1046	usd
CY2022	us-gaap	Depreciation Depreciation	523	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	80500	usd
CY2023	ivbt	Related Parties RelatedParties	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to Section 850-10-20 the related parties include (a) affiliates of the Company; (b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; (c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d) principal owners of the Company; (e) management of the Company; (f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a) the nature of the relationship(s) involved; (b) description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.</p>
CY2023Q3	us-gaap	Finite Lived Trademarks Gross FiniteLivedTrademarksGross	1680	usd
CY2022Q3	ivbt	Common Stock Issued For Asset Purchase Amount CommonStockIssuedForAssetPurchaseAmount	40654827	usd
CY2023	us-gaap	Schedule Of Closed Block Assets And Liabilities ScheduleOfClosedBlockAssetsAndLiabilities	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Mioxal®</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">81,249,827</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other intangible assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">178,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less liabilities assumed:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt">Mioxal® liability assumed </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(39,500,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt">Other liabilities assumed</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(423,000 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net value acquired in asset acquisition </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">41,504,827</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q4	ivbt	Mioxal Assets Fair Values MioxalAssetsFairValues	81249827	usd
CY2022Q4	ivbt	Other Intangible Assets OtherIntangibleAssets	178000	usd
CY2022Q4	ivbt	Mioxal Liability Assumed MioxalLiabilityAssumed	-39500000	usd
CY2022Q4	ivbt	Other Liabilities Assumed OtherLiabilitiesAssumed	-423000	usd
CY2022Q4	ivbt	Subtotal Subtotal	41504827	usd
CY2022Q3	ivbt	Intangible Assets IntangibleAssets	28773	usd
CY2022Q3	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.08	pure
CY2022	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	38638	usd
CY2022Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	17598	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	35780148	usd
CY2023	ivbt	Cash To Be Received By The Company CashToBeReceivedByTheCompany	100000	usd
CY2023	ivbt	Debt Assumed Forgiven By Buyer DebtAssumedForgivenByBuyer	39500000	usd
CY2023	ivbt	Imparement Expense ImparementExpense	-39554500	usd
CY2023	ivbt	Npv Of Estimated Future Royalty Cash Stream NpvOfEstimatedFutureRoyaltyCashStream	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.095
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0363	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.025	pure
CY2023	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	56531	usd
CY2023	ivbt	Outstanding Convertible Note Payable OutstandingConvertibleNotePayable	604180	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	508661	usd
CY2023Q3	us-gaap	Convertible Subordinated Debt ConvertibleSubordinatedDebt	95519	usd
CY2023	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	385181	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	150000	usd
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	619825	usd
CY2023	ivbt	Monthly Rent Description MonthlyRentDescription	The lease requires adjustment upon renewal with an increase to the monthly rent by 10% of the monthly rent due for the month preceding such renewal date or market rate, whichever is the greater amount
CY2023	ivbt	Summary Of Balance Sheet Data Related To Leases Textblock SummaryOfBalanceSheetDataRelatedToLeasesTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>August 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>August 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating lease right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">619,825</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less accumulated depreciation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(137,739 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total operating lease right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">482,086</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating lease liability, current</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">199,203</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating lease liability, noncurrent</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">298,423</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">497,626</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2023Q3	ivbt	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	0	usd
CY2022Q3	ivbt	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	619825	usd
CY2023Q3	us-gaap	Property Subject To Or Available For Operating Lease Accumulated Depreciation PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation	0	usd
CY2022Q3	us-gaap	Property Subject To Or Available For Operating Lease Accumulated Depreciation PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation	137739	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	482086	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	199203	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	298423	usd
CY2023Q3	us-gaap	Real Estate Subsidiary Liabilities RealEstateSubsidiaryLiabilities	0	usd
CY2022Q3	us-gaap	Real Estate Subsidiary Liabilities RealEstateSubsidiaryLiabilities	497626	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	480000	usd
CY2022Q4	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.05	pure
CY2023Q1	ivbt	Gain On Termination GainOnTermination	19236	usd
CY2023Q3	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	1748625	usd
CY2022Q3	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	837798	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	ivbt	Common Stock Transferred CommonStockTransferred	350000	shares
CY2023	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	450000	usd
CY2023	ivbt	Shares To Be Issuedshares SharesToBeIssuedshares	100000	shares
CY2023	ivbt	Shares To Be Issuedamount SharesToBeIssuedamount	22500	usd
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20470239	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20020239	shares
CY2023	us-gaap	Litigation Settlement Amount Awarded From Other Party LitigationSettlementAmountAwardedFromOtherParty	249020	usd
CY2023	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	30000	usd
CY2023Q3	ivbt	Potential Liability PotentialLiability	0	usd
CY2023Q2	ivbt	Potential Liability PotentialLiability	484668	usd
CY2023Q3	ivbt	Description Of Agreement Past Due Lease Payment DescriptionOfAgreementPastDueLeasePayment	The agreement calls for the Company to pay 40 Wall Street Suites LLC. a total of $40,000 as follows: (i) $20,000 within 15 days of complete execution of this letter agreement, and (ii) $20,000 within 45 days of complete execution of this letter agreement. In addition, the Company agrees and acknowledges that 40 Wall Street Suites LLC. shall be entitled to retain the security deposit previously made. In exchange for the payments and the related agreements 40 Wall Street Suites LLC. agrees not to take any action to pursue the litigation.
CY2023Q2	ivbt	Legal Proceeding LegalProceeding	264617	usd
CY2023Q3	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	920000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Statutory Accounting Practices Statutory Net Income Amount StatutoryAccountingPracticesStatutoryNetIncomeAmount	-1793000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Statutory Accounting Practices Statutory Net Income Amount StatutoryAccountingPracticesStatutoryNetIncomeAmount	-8545000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	555000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.065	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	2655000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.065	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Beat Amount EffectiveIncomeTaxRateReconciliationBeatAmount	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Beat Amount EffectiveIncomeTaxRateReconciliationBeatAmount	182000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.005	pure
CY2023	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	2348000	usd
CY2023	ivbt	Increase In Valuation Allowance Rate IncreaseInValuationAllowanceRate	-0.280	pure
CY2022	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	11392000	usd
CY2022	ivbt	Increase In Valuation Allowance Rate IncreaseInValuationAllowanceRate	-0.280	pure
CY2023	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	usd
CY2023	ivbt	Taxes On Income Loss Rate TaxesOnIncomeLossRate	0	pure
CY2022	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	usd
CY2022	ivbt	Taxes On Income Loss Rate TaxesOnIncomeLossRate	0	pure
CY2023Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3582000	usd
CY2022Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2163000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10774000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	9845000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14356000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12008000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2348000	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	150000	usd
CY2023	ivbt	Purchase Price Of Warrants PurchasePriceOfWarrants	0.08
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2205882	shares
CY2023	us-gaap	Malpractice Loss Contingency Discount Rate MalpracticeLossContingencyDiscountRate	0.18	pure
CY2023	ivbt	Maturity Date Of Note Description MaturityDateOfNoteDescription	13 months from original issuance
CY2023	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.08	pure
CY2023	ivbt	Conversion Price ConversionPrice	0.08
CY2023	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	0.08

Files In Submission

Name	View Source	Status
ivbt-20230831_def.xml	Edgar Link	unprocessable
ivbt-20230831_lab.xml	Edgar Link	unprocessable
ivbt-20230831_pre.xml	Edgar Link	unprocessable
0001477932-24-000223-index-headers.html	Edgar Link	pending
0001477932-24-000223-index.html	Edgar Link	pending
0001477932-24-000223.txt	Edgar Link	pending
0001477932-24-000223-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ivbt-20230831.xsd	Edgar Link	pending
ivbt_10k.htm	Edgar Link	pending
ivbt_10kimg3.jpg	Edgar Link	pending
ivbt_10kimg4.jpg	Edgar Link	pending
ivbt_ex311.htm	Edgar Link	pending
ivbt_ex321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
ivbt-20230831_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ivbt_10k_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Innovation1 Biotech Inc.

2024 Q1 Form 10-K Financial Statement

#000147793224000223 Filed on January 17, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission